Lumos Pharma

About Lumos Pharma

Lumos Pharma is a clinical-stage biopharmaceutical company focused on providing therapeutics for rare and neglected diseases.

The company was founded by Rick Hawkins, who serves as the Chairman, President, and CEO. His experience includes founding Pharmaco, where he also held the roles of Chairman, President, and CEO, managing the company through its IPO and subsequent acquisition. This background in building and leading pharmaceutical ventures is central to Lumos Pharma's strategy.

Originally established as NewLink Genetics Corporation in 1999, the company changed its name to Lumos Pharma in 2020. This rebranding coincided with a strategic shift to concentrate on the development of treatments for rare diseases.

The company's lead product candidate is LUM-201, an oral medication being developed for pediatric growth hormone deficiency and other rare endocrine disorders. This therapeutic is an orally administered growth hormone secretagogue, a type of drug that stimulates the pituitary gland to release growth hormone. The oral administration of LUM-201 offers a potential advantage over the standard injectable treatments for these conditions.

Lumos Pharma's business model is centered on the development and commercialization of its product pipeline. The company navigates the multi-phase process of clinical trials to establish the safety and efficacy of its therapeutics, with the ultimate goal of obtaining regulatory approval and bringing new treatments to market for patient populations with unmet medical needs.